clinical trial

Novartis Statement: Cystinosis Stem Cell Gene Therapy Program

In May 2023, Novartis acquired the investigational autologous hematopoietic stem cell (HSC) gene therapy program for the treatment of...

Press release originally published May 17, 2022 on Avrobio.com. New early data show key visual motor integration, visual perception...

Data from the AVROBIO Phase 1/2 investigational gene therapy for cystinosis was released today at WORLDSymposium in San Diego....

AVROBIO is looking for perspectives from the cystinosis community. They will be conducting a small focus group to help...

In a quarterly update, AVROBIO announced: “Data from the patients dosed to date across three indications continue to...

AVROBIO Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in...

November 17, 2020 – AVROBIO announced that data suggests functional and clinical improvements for the first cystinosis patient at...

Partnering with RDMD, this program aims to accelerate cystinosis research to ultimately improve treatment options. We welcome you to...

AVROBIO announces the second patient with cystinosis has been dosed in the company’s AVR-RD-04 investigational gene therapy Phase 1/2...

A letter from Fernanda Copeland, Executive Director, Head Patient Advocacy & Engagement at AVROBIO March 24, 2020 We hope...